How big is the 2020 biotech IPO boom? More than $11 bil­lion big among the year's four dozen en­trants

Last year
Financing

Covid-19 roundup: J&J plans 60,000-per­son PhI­II for Sep­tem­ber; Pe­ter Marks draws a red line

Last year
Coronavirus

De­railed gene ther­a­py study re­ports 3rd death as safe­ty and dura­bil­i­ty is­sues cloud a boom­ing field

Last year
R&D
Cell/Gene Tx

Bris­tol My­ers joins the lab rush in Cam­bridge with plans to con­sol­i­date R&D ops in a biotech cam­pus now un­der con­struc­tion

Last year
Pharma

Covid-19 roundup: Pfiz­er/BioN­Tech spell out PhI­II pri­or­i­ty; Le­gal ex­perts urge FDA to re­frain from vac­cine EUAs

Last year
Coronavirus

In an­oth­er shock­er, FDA re­jects Bio­Marin’s he­mo­phil­ia A gene ther­a­py, de­mand­ing more da­ta on dura­bil­i­ty

Last year
R&D
FDA+

J&J inks in­dus­try's lat­est bolt-on buy­out with $6.5B deal to ac­quire Mo­men­ta, beef­ing up its au­toim­mune pipeline

Last year
Deals

FDA hands Gilead a stun­ning re­jec­tion for block­buster RA can­di­date fil­go­tinib, deal­ing CEO O’Day a ma­jor set­back

Last year
R&D
FDA+

My­lan wins ear­ly FDA OK of a Tec­fidera knock­off, and they're launch­ing with an eye to top­pling Bio­gen's block­buster fran­chise

Last year
R&D
FDA+

An MD An­der­son study points to an­oth­er use for No­var­tis’ GSK-born can­cer drugs

Last year
R&D

Eli Lil­ly is bet­ting $1B-plus that it can make yet an­oth­er PD-1 drug a hit in the US. How about a deep dis­count this time?

Last year
R&D

Covid-19 roundup: In­side CTAP: 270 tri­als un­der­way, 570+ in the FDA line; WHO chief calls out 'vac­cine na­tion­al­is­m'

Last year
Coronavirus

New­ly ar­rived on Nas­daq, Po­sei­da qui­et­ly sig­nals a clin­i­cal hold trig­gered by a pa­tient death in PhI — shares crater

2 years ago
R&D
FDA+

Daniel O’Day’s I/O dance con­tin­ues, as Gilead and Tan­go ex­pand deal up to $6B

2 years ago
Deals
Cell/Gene Tx

Ned Sharp­less' 'brain­child' nabs a speedy FDA re­view for small cell lung can­cer drug

2 years ago
R&D
FDA+

In blow to an­ti-ag­ing field, Uni­ty Biotech­nol­o­gy fails first ma­jor study, cuts lead pro­gram

2 years ago
R&D

Covid-19 roundup: Just how much is the ‘first wave’ mar­ket for Covid-19 vac­cines worth? One top an­a­lyst sets the prize at $20B

2 years ago
Coronavirus

How bad­ly does Sanofi chief Paul Hud­son want Prin­cip­ia? Enough to ink a $3.7B buy­out deal, dou­bling down on MS

3 years ago
Deals

FDA ap­proves the third NMOSD drug in 18 months as Roche/Genen­tech beefs up its port­fo­lio of drugs for neu­ro­log­i­cal dis­or­ders

3 years ago
R&D
FDA+

US gov­ern­ment re­port­ed­ly be­gins prepar­ing for Covid-19 chal­lenge tri­als. Are they eth­i­cal?

3 years ago
R&D
Coronavirus

Covid-19 roundup: As­traZeneca signs 400M vac­cine sup­ply deal with EU; Sinopharm re­ports pos­i­tive Phase I/II da­ta for vac­cine can­di­date

3 years ago
Coronavirus

On the heels of a snap $1B raise, Cure­Vac out­lines plans to seek emer­gency OK for Covid-19 vac­cine -- shares rock­et up

3 years ago
Financing

FDA's ODAC shrugs off ob­jec­tions to Mesoblast's GVHD drug for chil­dren, vot­ing 9-1 in fa­vor and im­prov­ing the odds of an ap­proval

3 years ago
FDA+

Qi­a­gen in­vestors spurn Ther­mo Fish­er’s takeover of­fer, de­rail­ing a $12B+ deal

3 years ago
Deals
First page Previous page 111112113114115116117 Next page Last page